Abstract
Materials and Methods: A total of 45 patients who were determined to have pN2 disease after pneumonectomy between 2007 and 2016 were retrospectively analyzed. The patients were assigned a GPS between 0 and 2 as follows: elevated CRP level (>1.0 mg/dL) and hypoalbuminemia (<35 mg/dL) was classified as GPS 2, elevated CRP but albumin >35 mg/dL was classified as GPS 1, and CRP <1.0 mg/dl and albumin >35 mg/dL were classified as GPS 0.
Results: Of the 45 patients included in the study, 42 (93.3%) were male and 3 (6.7%) were female. Eighteen (40%) of the patients had adenocarcinoma and 27 (60%) had squamous cell carcinoma. Skip pN2 (pN0N2) was detected in 10 patients. Mean follow-up time was 28 months. The 5-year survival rate was 40.2%. The main prognostic factors associated with survival were GPS and adjuvant therapy (p = 0.023, p = 0.001).
Conclusions: In this study, there was no relationship between N1 status and survival in pneumonectomy patients with pN2 NSCLC, whereas GPS score and adjuvant therapy were found to be prognostically significant in terms of survival.
Introduction
The aim of the present study was to investigate the factors affecting survival in pneumonectomy patients found to have N2 disease and to evaluate the relationship between GPS and survival in NSCLC.
Materials and Methods
){kind=link}
 Click Here to Zoom |
Figure 1: Study flow chart. |
Patients found to have single station pN2 were divided into two groups:
i. Patients with single station pN2 skip metastasis (pN0N2)
ii. Patients with single pN1 and single pN2 involvement (pN1N2)
Preoperative Assessment
All patients underwent thoracic computed tomography (CT), positron emission tomography (PET-CT), and cranial magnetic resonance imaging (MRI) during preoperative assessment. Respiratory function tests and electrocardiogram were performed to evaluate pulmonary and cardiac reserve. Carbon monoxide diffusion test and lung perfusion scintigraphy were also done for patients with forced expiratory volume in the first second (FEV1) less than or equal to 40% of the predicted value. Patients with a history of cardiac disease and those aged 60 years or older were evaluated with echocardiogram by a cardiologist. In addition, all patients were examined preoperatively by fiberoptic bronchoscopy. Invasive mediastinal staging was performed by EBUS or mediastinoscopy in all patients with findings of pathological mediastinal lymph node in radiological imaging. The IASLC 2009 lymph node map was used for mediastinal lymph node classification [5].
GPS was determined based on serum CRP and albumin levels before and after surgical treatment. Patients with both high CRP (>1.0 mg/dL) and low albumin (<35 mg/dL) were classified as GPS 2, patients with high CRP but albumin >35 mg/dL were classified as GPS 1, and patients with CRP <1.0 mg/dl and albumin >35 mg/dL were classified as GPS 0.
Postoperative Follow-up
Early mortality was defined as deaths that occurred in hospital or within the first postoperative month. Follow-up information was obtained from all patients through office visits or telephone interviews either with the patient, a relative, or their primary physicians. The patients were followed up by oncologists with thoracic CT and physical examination every 3 months for the first 2 years, every 6 months between 2 and 5 years, and once a year thereafter.
Statistical Analysis
The differences in proportions between groups were compared by using Chi-Square test. Difference between two groups for continuous variables was evaluated by Student’s test. Mann-Whitney U test was used to test the difference between two groups in terms of ordinal or non-normally distributed continuous variables. Survival analysis was conducted using the Kaplan–Meier method and curves were compared using the log-rank test. The level of statistical significance was accepted as p < 0.05 for all analyses.
Results
){kind=link}
Table 1: Comparison of demographic and clinical characteristics of the patients.
Two patients died within the first postoperative month. No statistically significant association was detected between GPS and early mortality (p = 0.509). Eight patients (17.8%) did not receive adjuvant therapy postoperatively due to unstable general condition or refusal of medical treatment.
Mean follow-up time was 28 ± 24.76 months. The 5-year survival rate was 40.2% (median 32 months). The main prognostic factors associated with survival were found to be GPS and adjuvant therapy (p = 0.023, p = 0.001). Prognostic factors associated with survival are shown in Table 2 (Figure 2).
){kind=link}
){kind=link}
Table 2: Factors associated with survival in pN2 NSCLC patients after pneumonectomy.
 Click Here to Zoom |
Figure 2: (A) Kaplan–Meier survival curves for overall survival, (B) according to GPS value, (C) Cancer stage, (D) pN2 status. |
Discussion
In our study, we found that low GPS was among the factors associated with longer survival in pN2 patients who underwent pneumonectomy. The 5-year survival rate was 62.6% for GPS 0 patients versus 27.1% for patients with GPS 1–2 (p = 0.023). In their study on 272 patients with colorectal carcinoma, Nozoe et al. found that survival was significantly worse in GPS 1 patients compared to GPS 0 patients (p = 0.009) and in GPS 2 patients compared to GPS 1 patients (p < 0.0001). Similarly, survival was significantly worse in modified Glasgow Prognostic Score (mGPS) 1 patients compared to mGPS 0 patients (p = 0.009) and in mGPS 2 patients compared to mGPS 1 patients (p = 0.006) [13]. In a meta-analysis by Jin et al. [12] evaluating 5369 NSCLC patients treated with surgery and/or chemotherapy, it was found that elevated CRP levels were associated with shorter survival time (HR = 2.058; 95% CI: 1.51–2.80; p < 0.05). In the same study, survival rate was lower with GPS ≥ 1 compared to GPS 0 (p < 0.001). Minami et al. [14] reported that mGPS was not associated with survival in stage 3B and 4 squamous cell carcinoma patients who received first-line cytotoxic chemotherapy after curative surgery or radiotherapy (p = 0.61).
National Comprehensive Cancer Network (NCCN) guidelines recommend adjuvant chemotherapy for patients determined to have N1 and N2 disease following NSCLC surgery [15]. In their study of patients who received adjuvant therapy after curative resection, Park et al. [16] reported longer disease-free survival after full-dose chemotherapy. In the literature, it can be seen that survival rates are significantly lower among patients who do not receive adjuvant therapy. Speggiari et al. [17] found that the 5-year survival rate in potential N2 patients who received chemotherapy after surgery was 18%, while the survival rate in patients who received chemotherapy alone or chemoradiotherapy alone was 8% (p = 0.02). In our study, postoperative adjuvant therapy was associated with higher survival rate after pneumonectomy in pN2 patients when compared with patients who did not receive adjuvant therapy (p < 0.001).
Skip N2 is observed in 17.2-42.3% of pN2 NSCLC patients [18]. There is still no clear consensus on whether skip N2 has a better prognosis than non-skip N2 [19,20]. This is primarily due to the heterogeneity of pN2 disease. In our study, patients with pN0N2 disease had better 5-year survival than patients with pN1N2. Although these results are similar to those in the literature, there have been some publications indicating otherwise [21]. Legras et al. [22] reported a 5-year survival rate of 25% in patients with N2 disease. Survival was worse in pure N2 patients who were also pN1 (5-year overall survival rate 21% vs. 34%, HR = 2.09, p < 0.001). Similarly, Yazgan et al. [23] also reported much better survival in pure N2 disease compared to pN1N2.
The main limitations of this study are the small patient group and its retrospective design. Furthermore, although it was a single-center study, the surgeries were performed by different surgeons.
In conclusion, based on the findings of this study, N1 status did not affect survival in N2 patients who underwent pneumonectomy due to NSCLC, whereas GPS and adjuvant therapy were significant prognostic factors. Therefore, we believe that assessment with GPS may be beneficial for patients planned to undergo resection in order to determine postoperative prognosis.
Declaration of conflicting interests
The authors declared no conflicts of interest with respect to the authorship and/or publication of this article.
Funding
The authors received no financial support for the research and/or authorship of this article.
Ethics approval
The study was approved by the Ethics Committee of Health of Science University (No: 20189/1525).
Authors’ contributions
CA; Performed the analysis, co-wrote the paper, contributed data/analysis tools, CBS; performed the analysis, co-wrote the paper, AC, MVD; co-wrote the paper, YA, CEK,VE; Collected the data, LC, MM; Contributed data, co-wrote the paper.